Resource Summary Report

Generated by RRID on Aug 9, 2026

Anti-MEK1, phospho (Ser298) Antibody, Unconjugated

RRID:AB_330810
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9128, RRID:AB_330810

Antibody Information

URL: http://antibodyregistry.org/AB_330810

Proper Citation: Cell Signaling Technology Cat# 9128, RRID:AB_330810

Target Antigen: MEK1, phospho (Ser298)

Clonality: unknown

Comments: Applications: W

Antibody Name: Anti-MEK1, phospho (Ser298) Antibody, Unconjugated

Description: This unknown targets MEK1, phospho (Ser298)

Target Organism: monkey, rat, simian, mouse, human

Antibody ID: AB_330810

Vendor: Cell Signaling Technology

Catalog Number: 9128

Record Creation Time: 20250820T012858+0000

Record Last Update: 20250820T110257+0000

Ratings and Alerts

No rating or validation information has been found for Anti-MEK1, phospho (Ser298) Antibody, Unconjugated.

No alerts have been found for Anti-MEK1, phospho (Ser298) Antibody, Unconjugated.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer research, 85(9), 1611.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. Cell reports, 42(12), 113486.

Schaefer A, et al. (2023) RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling. Science signaling, 16(816), eadg5289.

Ausejo-Mauleon I, et al. (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell, 41(11), 1911.

Cho E, et al. (2021) PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. Cell reports, 34(13), 108928.

Nassar KW, et al. (2021) Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Molecular cancer therapeutics, 20(10), 2049.

Ozkan-Dagliyan I, et al. (2020) Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell reports, 31(11), 107764.